SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Oncology Pharmacy Practice
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Trissel, L. A.
Right arrow Articles by Zhang, Y.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Trissel, L. A.
Right arrow Articles by Zhang, Y.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin, and oxaliplatin during simulated Y-site administration

Lawrence A. Trissel, BSc

Clinical Pharmaceutics Research, Division of Pharmacy, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA

Yanping Zhang, BSc

Clinical Pharmaceutics Research, Division of Pharmacy, University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA

The objective of this study was to evaluate the physical and chemical stability of undiluted palonosetron HCl 50 mcg/mL with cisplatin 0.5 mg/mL, carboplatin 5 mg/mL, and with oxaliplatin 0.5 mg/mL in infusion solutions during simulated Y-site administration.

Triplicate test samples were prepared by admixing 7.5 mL of palonosetron HCl with 7.5 mL of the cisplatin, carboplatin, and oxaliplatin dilutions. Physical stability was assessed using a multistep evaluation procedure that included both turbidimetric and particulate measurement as well as visual inspection. Chemical stability was assessed using stability-indicating HPLC analytical techniques based on the determination of drug concentrations. Evaluations were performed initially upon mixing and 1 and 4 hours after mixing.

The samples were clear and colourless when viewed in normal fluorescent room light and when viewed with a Tyndall beam. Measured turbidity remained unchanged and particulate content was low and exhibited little change. HPLC analysis found palonosetron HCl, cisplatin, carboplatin, and oxaliplatin remained stable throughout the 4-hour test with no drug loss.

Palonosetron HCl is physically compatible and chemically stable with cisplatin, carboplatin, and oxaliplatin during Y-site administration.

Key Words: carboplatin • cisplatin • compatibility • oxaliplatin • palonosetron • stability

Journal of Oncology Pharmacy Practice, Vol. 10, No. 4, 191-195 (2004)
DOI: 10.1191/1078155204jp136oa


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
T. C. Kupie, C. Trusley, M. Ben, and L. A. Trissel
Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration
Am. J. Health Syst. Pharm., September 15, 2008; 65(18): 1735 - 1759.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
L. A. Trissel, C. Trusley, M. Ben, and T. C. Kupiec
Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration
Am. J. Health Syst. Pharm., June 1, 2007; 64(11): 1209 - 1213.
[Abstract] [Full Text] [PDF]



Advertisement